HCM as reported
HUTCHMED (China) Limited reported $205M of revenue over the trailing twelve months. 8 reported series are charted on this page, each one as filed.
$205M
Revenue, trailing twelve months · to Q4 2019 · every figure below is as filed, with no scoring applied
- Net Income
- −$106M
Net Income · trailing twelve months to Q4 2019
- Free Cash Flow
- −$89M
Free Cash Flow · trailing twelve months to Q4 2019
- Op Margin
- −71%
Op Margin · trailing twelve months to Q4 2019
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $205M | n/a | Q4 2019 |
| Net Income | −$106M | n/a | Q4 2019 |
| Op Margin | −71% | n/a | Q4 2019 |
| Net Margin | −52% | n/a | Q4 2019 |
| ROE | −28% | n/a | Q4 2019 |
| ROA | −19% | n/a | Q4 2019 |
| ROIC | −88% | n/a | Q4 2019 |
| Free Cash Flow | −$89M | n/a | Q4 2019 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
HUTCHMED (China) Limited (HCM) - Revenue & ProfitRevenue & ProfitHUTCHMED (China) Limited (HCM)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Drug Manufacturers - Specialty & Generic
The closest names by size in the same industry